معرفی
Gregory Verdine is the Erving Professor of Chemistry at Harvard University, with primary appointments in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology. He is a pioneering figure in chemical biology, DNA repair mechanisms, and therapeutic modality development, particularly known for inventing stapled peptides that target previously "undruggable" proteins. Verdine also serves as Chairman of the Board of Directors at WaVe Life Sciences and President/CEO of FogPharma, while maintaining advisory roles at institutions like Memorial Sloan-Kettering Research Institute and National Cancer Institute.
- Harvard University (Stem Cell and Regenerative Biology, Chemistry and Chemical Biology)
- Founder/Co-Founder of 8 biotech companies (Enanta, Gloucester, Tokai, WaVe, Eleven Biotherapeutics, Warp Drive Bio, Aileron, FogPharma)
- Non-Profit Leadership: Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy
Research focuses on chemical biology and genomic stability, with key discoveries in:
- Molecular mechanisms of epigenetic DNA methylation
- Genotoxic DNA damage surveillance pathways
- Design of stapled peptides for protein-protein interaction modulation
- Applications in oncology (β-catenin, Ras, RAB25 targeting)
- Advancing nucleotide excision repair systems
- Antisense oligonucleotide stereochemical optimization
His 15 most recent publications (2013-2024) reveal trends in:
- Covalent enzyme inhibitors
- Genomic modality discovery
- Ubiquitin ligase reprogramming
- Protein structure remodelling
- Allele-selective genetic therapies
- DNA lesion recognition mechanisms
Awards include the 2024 AACR Award for Excellence in Chemistry in Cancer Research and Nobel Laureate Signature Award. He has translated academic research into clinical applications through multiple FDA-approved drugs (romidepsin, paritaprevir) and currently leads FogPharma's Cell-Penetrating Miniprotein platform. Academic collaborators span Harvard, MIT, and major biomedical research institutions.
